News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sciele Pharma, Inc. (SCRX) Announces Acceptance by FDA of sNDA for New Sular Formulation


9/4/2007 11:09:32 AM

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Sciele's new Sular formulation, with a Pharmacy Drug User Fee Act (PDUFA) date of November 2, 2007. The new Sular formulation utilizes SkyePharma's (LSE:SKP) patented Geomatrix™ technology, which is designed to provide a lower dose of Sular for each of its current doses.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES